Docket: T-1659-15
Citation:
2016 FC 229
Ottawa, Ontario, February 22, 2016
PRESENT: The
Honourable Madam Justice McDonald
BETWEEN:
|
NOVARTIS AG
|
Applicant
|
and
|
THE ATTORNEY
GENERAL OF CANADA
|
Respondent
|
JUDGMENT AND REASONS
[1]
This is an Application by Novartis AG (Novartis)
pursuant to sections 31(3) and 52 of the Patent Act, RSC 1985 c P-4 (Patent
Act) to vary all entries in the records of the Patent Office with respect
to the inventorship of Canadian Patent No. 2,782,650 (the ‘650 Patent).
[2]
Novartis is the registered owner of the ‘650
Patent with respect to “arranging interaction and back
pressure chambers for microfluidization” and is therefore an interested
party for the purpose of section 52 of the Patent Act.
[3]
The Application is supported by a Declaration of
Barbara Santry, dated March 23, 2015, consenting to removing her name as an
inventor from the registration of the ‘650 Patent. It is also supported by the
Declaration of inventor Harald Rueckl, dated March 20, 2015, and the Declaration
of inventor Hanno Scheffczik, dated March 24, 2015, both confirming that
Barbara Santry did not contribute to the invention and that she was incorrectly
named as an inventor.
[4]
The Attorney General of Canada is not contesting
this Application and has not filed an Affidavit or a Brief.
[5]
The jurisdiction of the Federal Court on an
application to amend the inventorship of an issued patent is reviewed in Micromass
UK Ltd v Canada (Commissioner of Patents), 2006 FC 117 as follows:
[12] After the patent has issued, the
Commissioner has no discretion, under section 8 of the Act or otherwise, to
amend the inventorship of an issued patent. Such action falls exclusively
within the jurisdiction of the Federal Court. Specifically, section 52 of the
Act provides that the Federal Court has jurisdiction, on the application of the
Commissioner or of any person interested, to order that any entry in the
records of the Patent Office relating to the title to the patent be varied or
expunged.
[13] The word “title” in section 52 of
the Act is broader than acquisition by assignment and covers matters relating
to the root of title. The jurisdiction of the Court extends to correcting
inadvertent errors relating to the naming of the inventors of an issued patent,
including errors of a clerical nature relating to the transcribing of inventor
names: BF Goodrich v. Commissioner of Patents (1960), 32 C.P.R. 122
(SEC.I) (Ex. Ct.).
[14] An application under section 52 of
the Act may be brought by an assignee of a patent, with notice to the
Commissioner, by way of an originating process or by way of notice of motion
during a pending infringement case relating to the patent in question. The
assignee must notify any persons who are claiming an interest in the patent,
and if there is a pending infringement case involving the patent at issue, any
persons that may have a defence that could be affected by the order sought: Clopay
Corporation and Canadian General Tower Ltd. v. Metalix Ltd. (1960), 34
C.P.R. 232 (Ex. Ct.) aff'd. (1961), 39 C.P.R. 23 (S.C.C.).
[15] The powers conferred on the Court
under section 52 are very broad. In Clopay, Cameron J. described section
54 (now section 52) of the Act in the following manner
...I think, therefore, that s. 54 was
enacted so as to enable the rectification by the Court of the records in the
Patent Office relating to title in order that the party or parties actually
entitled to the grant or to be registered as to the assignees of the patent,
might have their rights properly recorded (p. 235)
[...]
I am of the opinion, however, that
the provisions of s. 54 of our Patent Act are by themselves sufficiently
broad to encompass a situation such as the one before me, in which the grantee
of the patent was dissolved prior to the grant, and that there is power in the Court
to direct that the records be corrected to accomplish that which the
Commissioner would have done had the two assignments now recorded been
registered prior to the grant (p. 236).
[16] It is immaterial to the public
whether there is one inventor or two joint inventors as this does not go to the
term or to the substance of the invention nor even to entitlement Apotex
Inc. v. Wellcome Foundation Ltd. (1998), 79 C.P.R. (3d) 193 (F.C.T.D.)
appeal allowed in part, but not on this issue (2000), 10 C.P.R. (4th) 65
(F.C.A.) aff'd. (2002), 21 C.P.R. (4th) 499 (S.C.C.).
[6]
The test to be meet on a section 31(3)
application is outlined as follows:
31.(3) Where an
application is filed by joint applicants and it subsequently appears that one
or more of them has had no part in the invention, the prosecution of the
application may be carried on by the remaining applicant or applicants on
satisfying the Commissioner by affidavit that the remaining applicant or
applicants is or are the sole inventor or inventors.
|
31.(3) Lorsqu’une
demande est déposée par des codemandeurs et qu’il apparaît par la suite que
l’un ou plusieurs d’entre eux n’ont pas participé à l’invention, la poursuite
de cette demande peut être conduite par le ou les demandeurs qui restent, à
la condition de démontrer par affidavit au commissaire que le ou les derniers
demandeurs sont les seuls inventeurs
|
[7]
The Applicant relies upon the Declarations of
three individuals. Barbara Santry is employed as a Site Head for Manufacturing
Science and Technology at Novartis. She states that she was not an inventor of
the invention contemplated in the ‘650 Patent and she consents to the removal
of her name as an inventor. The other listed inventors, Harald Rueckl and Hanno
Scheffczik, also confirm that Barbara Santry did not contribute to the
invention and was incorrectly named as an inventor. According to the evidence
filed with this Application, the related United States patent applications have
already been varied to remove Barbara Santry as an inventor.
[8]
Therefore the evidence is uncontradicted and the
interested parties agree that the inclusion of that Barbara Santry as an
inventor on this patent was an error. The Commissioner of Patents has not
opposed the application and nothing suggests that third party rights will be
affected.
[9]
This evidence meets the requirements of
subsection 31(3) of the Patent Act. Accordingly, the order sought by
Novartis to amend the Patent Office’s records by removing the name of Barbara
Santry as an inventor of the ‘650 Patent should be granted.